Fangda acted as the PRC legal counsel to Akeso, Inc. (HKEX: 9926) in its recently completed overseas share placement. The total proceeds raised amounted to approximately HKD3.522 billion, which will primarily be used to support global and China R&D of innovative pipeline, research on technology platforms and building of infrastructure and facilities, commercialization of existing approved products, and general corporate purposes.
Akeso is a biopharmaceutical company dedicated to the research, development, manufacture, and commercialization of innovative antibody drugs that are affordable for patients worldwide. It is the only PRC biopharmaceutical company selected to the “Breakthrough” category of the recently announced “Fierce 50 of 2025” list. Its self-developed, first-in-class PD-1/VEGF bispecific antibody drug, Ivonescimab, was also selected to the “Most Valuable R&D Projects” list released by Evaluate, a leading global healthcare consultancy and market research provider. Ivonescimab is the only drug developed by a PRC innovative biopharmaceutical company to be recognized on this prestigious list.
Fangda has participated throughout Akeso’s overseas fundraising activities in recent years, including its previous placements completed in March 2024 and October 2024 on the Hong Kong Stock Exchange, and has assisted Akeso in completing the filing procedures with the China Securities Regulatory Commission. The project was led by partners and . Team members included and Zheng Chunyuan.
